/l WBC. Creactive protein was 130 mg/1 and fibrinogen was 7 g/1. Immunoelectrophoresis showed a polyclonal increase in serum immunoglobulins (IgG 24.8 g/1, IgA 9.26 g/1, IgM 0.66 g/1) with a monoclonal IgA kappa. Direct Coombs test, antinuclear antibodies and viral serological tests (Epstein-Barr virus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus) were negative. Plasma cytokines were elevated: IL-6 at 85 pg/1 (<20 pg/1), soluble IL-2R at 239 pg/1 (< 190 pg/1) and tumor necrosis factor-a (TNF-a) at 32 pg/1 (<10 pg/1). Abdominal CT scan confirmed hepatosplenomegaly and enlarged lymph nodes in the upper caval and abdominal aortic regions. Biopsy of a cervical lymph node showed a typical giant cell hyperplasia consistent with MCD.
IFN-a (4.5 x 10 6 UI s.c. three times a week) was then initiated (June 1996). After one month of treatment, B symptoms were resolved and laboratory tests were normal. Six months later, a 50% lymph node decrease was noted, and IFN therapy was reduced (3 UI x 10 6 3 times a week). No flu-like syndrome was noted. One year after the diagnosis, the patient was in complete remission and IFN-a was stopped. The patient has remained in remission up to now (April 2000). Patients with MCD are candidates for multimodality therapy, the nature of which has yet to be defined [1] [2] [3] [4] . Limited data are available regarding the treatment of MCD (% and duration of response, side effects of therapy, no prospective study) [1] .
Pavlidis and Tamayo have reported the efficacy of IFN-a in two previously treated MCD [5, 6] . In these two cases, the authors described rapid complete remission (follow-up, respectively, 11 and 32 months). Our experience suggests that IFN-a may play a role as a first-line therapy in MCD. In fact, INF therapy induces long-term remission (follow-up 42 months), rapid improvement in B symptoms and normalization of laboratory tests (< 1 months). In lower doses (3-5 x 10 6 UI s.c. 3 times a week), INF-a had also limited toxicity.
Similar to retinoic acid in MCD, responses to IFN-a may result from down regulation of IL-6R (modulation of UL-6/IL-6R autocrine/paracrine loop), from positive effects on endothelial dysfunction (as in KasabachMeritt syndrome) or from anti-viral human herpes virus 8 efficacy [1, 3, 4] .
